Quality-of-life effects of prostate-specific antigen screening. - Wikidata - awgldk - TriplyDB

Quality-of-life effects of prostate-specific antigen screening.

Quality-of-life effects of prostate-specific antigen screening.

http://www.wikidata.org/entity/Q34294102

about

Screening for prostate cancer Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer Screening Coverage Needed to Reduce Mortality from Prostate Cancer: A Living Systematic Review Overdiagnosis and overtreatment of prostate cancer Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles Screening guidelines for non-AIDS defining cancers in HIV-infected individuals Active surveillance for prostate cancer: current evidence and contemporary state of practice Prostate cancer screening in Brazil: should it be done or not?A Review of Experimental and Off-Label Therapies for Clostridium difficile Infection Quantifying Gleason scores with photoacoustic spectral analysis: feasibility study with human tissues.A reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada.Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.[The parameter "relative survival": Analysis of regional cancer registry data for prostate cancer].Prostate cancer screening: a complicated puzzle, explanation needed Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by Fluorescence Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.Prostate-specific antigen screening in prostate cancer: perspectives on the evidence Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq.Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.Effects of surgeon variability on oncologic and functional outcomes in a population-based setting What do the screening trials really tell us and where do we go from here?Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada A snapshot of cancer in Chile: analytical frameworks for developing a cancer policy PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.Ethnicity and prostate cancer: the way to solve the screening problem?TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges.Mode of prostate cancer detection is associated with the psychological wellbeing of survivors: results from the PiCTure study.Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors Divorcing diagnosis from treatment: contemporary management of low-risk prostate cancer.Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.Absolute Effect of Prostate Cancer Screening: Balance of Benefits and Harms by Center within the European Randomized Study of Prostate Cancer Screening.Mutational load of the mitochondrial genome predicts pathological features and biochemical recurrence in prostate cancer.

P2860

Q24201690-D876E09B-3EF1-43BC-BB21-F9D71C84F55B Q26739708-BDBDF8AA-69DE-4ECE-906A-44F0809CDDC3 Q26748873-8B6A4C5C-77BD-4F42-A565-8BAAD29DEEDD Q26859596-37D5450C-D2D0-4D52-B1EF-AB558375FB04 Q26865810-4D79EF00-CA8B-4B32-A123-8C26D57EBCDC Q27021899-F2C40880-7FD2-48D2-9AC0-F89619C5C32C Q28066534-382C5A3E-5E78-461F-83B4-9F0A18CB620C Q28068688-3AE81232-2496-4076-A69F-57B85750AE39 Q30240264-0EB9508C-F68F-4F4B-91E6-60306ACE1655 Q30395328-6280CA8D-4D20-4BC7-8B91-5CD5A76B17CA Q30613075-D51C356A-31B9-4674-8654-7365806A7E39 Q30878080-4915609F-24A5-4CFE-BFE2-80A0CBF0167E Q30992920-6B401B63-7E34-4AA7-BEC9-AD932587C5BD Q33356114-89E8885E-7EC5-4AFC-974B-B9F34BCFF1D1 Q33651094-EE323748-D489-4E46-B310-368B4F679E22 Q33750148-99629445-7DFF-45BA-8FE5-845E195A5D73 Q33759991-B2B1BB82-8AA6-4957-B704-7751375B7DA5 Q33836709-9A9059F1-A054-43A2-A475-081177E7BBD5 Q33978331-5C85B2B1-077C-4C55-A8D1-DCD097FA5732 Q34041688-56668A3A-FDA5-4FC7-AFC7-56EA02DD29EB Q34159375-8146E9BB-CACC-45D2-A204-38B4E185DCFF Q34326169-6825F4E3-8CC4-42AE-89E1-CF6FF3DDA69E Q34354430-6A4A4C52-11F7-49F7-B4C8-1582AED51D57 Q34467274-D0003DF0-A9B6-41D6-B944-ED8C79FCB949 Q35089983-9B36C2D4-213C-4704-998A-099452F503CC Q35112495-824509A6-7A57-405C-9C37-E1574696B411 Q35234770-66CEFAAF-6B04-4863-8E41-86A5D81C0BE0 Q35541638-C6361204-F69B-4194-ABF2-588E9EEAB058 Q35562601-47E6825A-81DB-4E26-8EF2-9E0C47078361 Q35700730-A3AE1009-7D76-4CA2-9CB7-4BE126DBDDC8 Q35736485-CEC86765-094C-4719-B3EB-AAB71A3B8389 Q36067872-3A1653A3-2788-4623-8C04-803B3AD04DA8 Q36546399-CA1CE3BA-D02A-41F7-895F-4344CD8F75EF Q36723934-696730E6-C358-4854-812E-2843571E8909 Q36896116-AF5ADBFF-9310-46AB-9A5C-2DDAA3FE9DE5 Q37025434-FA687C7A-F162-45A3-A35D-B4CCC2C61607 Q37095655-2ED396E6-F03B-4BE8-B2F5-235A0A12D58E Q37103771-AF9C4E58-056B-4B76-BBFE-1245457DBB29 Q37109441-C3CB10B9-6411-4AEE-AAF8-517DA229CBB7 Q37538185-77F37358-202D-4856-AF6C-8A0E5B067603

P2860

Quality-of-life effects of prostate-specific antigen screening.

http://www.wikidata.org/entity/Q34294102

description

2012 nî lūn-bûn

@nan

2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Quality-of-life effects of prostate-specific antigen screening.

@ast

Quality-of-life effects of prostate-specific antigen screening.

@en

Quality-of-life effects of prostate-specific antigen screening.

@nl

type

label

Quality-of-life effects of prostate-specific antigen screening.

@ast

Quality-of-life effects of prostate-specific antigen screening.

@en

Quality-of-life effects of prostate-specific antigen screening.

@nl

prefLabel

Quality-of-life effects of prostate-specific antigen screening.

@ast

Quality-of-life effects of prostate-specific antigen screening.

@en

Quality-of-life effects of prostate-specific antigen screening.

@nl

P1433

Q34294102-1B2F43CC-F914-4C0D-92BB-15654FC5E39C

P1476

Q34294102-D10805B6-3202-4D6E-925A-795410EF2762

P2093

Q34294102-18BD00BB-3761-4C9A-895D-C51E73428B73

Q34294102-28CA7983-7BB0-4759-B196-2D3CC569B1B3

Q34294102-3E29C6E1-F94B-484A-98F0-3B44DA284B06

Q34294102-4D863C0F-555E-4266-BA3A-6D45411267C4

Q34294102-51100EB8-908C-4331-B687-AF1AB9DBA86A

Q34294102-519E500A-A331-4682-97FC-CD4B53FDE87A

Q34294102-6D70DE86-8A72-4360-99A2-60647B9B08F5

Q34294102-848BC0B4-64D7-40D0-A286-9EC03AFA7634

Q34294102-8583B9EB-0930-4B10-9E22-73AD6A895868

Q34294102-90860914-52EC-439C-92AF-479E5648D062

P2860

Q34294102-01EEFE79-17D5-4797-9E3B-C95490526CC8

Q34294102-04D38591-0999-4A7A-AE55-EB94DC82BE1A

Q34294102-0C942FF8-5405-4F1D-878C-3908A0AF8BEB

Q34294102-109EC9F2-32A4-42AF-A2F7-998568664F0C

Q34294102-13314CC3-0D24-425E-B07D-B6AACA59BA93

Q34294102-20B3A5E5-7335-4621-A774-67C1FFD9977C

Q34294102-313E0EA7-FD4B-4C82-B68C-19D508AC2D03

Q34294102-39DF853C-5FD3-411F-B012-294A4ED17F98

Q34294102-3C26BC0D-B38D-4375-BB0E-96ED5DC5C0B9

Q34294102-4D96CCAD-E25A-4FE1-BD58-83C6F78C2A75

P304

Q34294102-4BD3876B-C66E-433F-9F70-80F90D7AA279

P31

Q34294102-85924DAF-C30D-485B-91C0-917991A40492

P356

Q34294102-A9838A72-07FB-4385-A979-CFE0FA4759DF

P407

Q34294102-7EA5AD9A-CA74-4220-AFDF-B4594B1A11D6

P433

Q34294102-730065CB-C170-41F2-91BC-6A2340F84C8A

P478

Q34294102-0D2BF03F-086E-40B2-81D9-920799DF0FD3

P50

Q34294102-0DC72B42-5D09-48C9-9C74-F0B09579DD84

Q34294102-2E428EBB-7586-4276-9861-1E538D6239B3

Q34294102-50B41C3B-7C4B-4E1F-9455-D3E11D48AB86

Q34294102-E2F3172A-871F-4640-A6DB-AFE72F5E08E9

P577

Q34294102-76E5EE88-1729-4C55-9770-FEB0D86A238B

P5875

Q34294102-9529AC87-E3C4-4F8E-B629-E9A42ABA88A8

P698

Q34294102-7FDAB6E5-7525-4C26-A91D-A980DCF348DB

P921

Q34294102-9F64604A-1153-4777-8406-FDB3ED4B76E9

P932

Q34294102-DA2F460F-9DDD-49EA-B42C-0FA14827B762

P356

P1433

The New England Journal of Medicine

P1476

Quality-of-life effects of prostate-specific antigen screening

@en

P2093

Alvaro Páez

http://www.w3.org/2001/XMLSchema#string

Chris H Bangma

http://www.w3.org/2001/XMLSchema#string

Elisabeth M Wever

http://www.w3.org/2001/XMLSchema#string

Eveline A M Heijnsdijk

http://www.w3.org/2001/XMLSchema#string

Fritz H Schröder

http://www.w3.org/2001/XMLSchema#string

Gerrit Draisma

http://www.w3.org/2001/XMLSchema#string

Harry J de Koning

http://www.w3.org/2001/XMLSchema#string

Ida J Korfage

http://www.w3.org/2001/XMLSchema#string

Jonas Hugosson

http://www.w3.org/2001/XMLSchema#string

Maciej Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Active surveillance for prostate cancer: progress and promise

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

Short-term effects of population-based screening for prostate cancer on health-related quality of life

Screening and prostate-cancer mortality in a randomized European study

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer.

Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer

The story of the European Randomized Study of Screening for Prostate Cancer.

P304

595-605

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1201637

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

367

http://www.w3.org/2001/XMLSchema#string

P50

Marie-Louise Essink-Bot

Arnauld Villers

P577

2012-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230677499

http://www.w3.org/2001/XMLSchema#string

P698

22894572

http://www.w3.org/2001/XMLSchema#string

P921

quality of life

P932

4982868

http://www.w3.org/2001/XMLSchema#string